Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Taiho Licenses Antiemetic Combination Drug from Helsinn
April 25, 2011
- Takeda, Samyang to Collaborate for RNAi DDS Tech
April 25, 2011
- New ARB EDARBI Launched in the US: Takeda
April 25, 2011
- Takeda Starts PIII Trial of AMG479 in Metastatic Pancreatic Cancer
April 25, 2011
- Tsumura Establishes Licorice Cultivation Methods in China
April 25, 2011
- OPF to Codevelop DIABECELL with LCT for Islet Replacement Therapy
April 25, 2011
- Mochida to Resume Full Production of Oral Drugs by Late June
April 25, 2011
- CytRx to Develop TMRC's Tamibarotene for NSCLC in North America
April 25, 2011
- Mohrus Tape Production Partially Recovers at Hisamitsu Factory
April 25, 2011
- Shipment of Hundreds of Drug Brands Affected by Quake
April 25, 2011
- NEW PRODUCTS
April 25, 2011
- Bayer Yakuhin Aims at Sales of Over ¥200 Bil. in 2-3 Years
April 25, 2011
- Xience V More Significantly Reduces MACE than Taxus: Abbott
April 25, 2011
- Novartis Discontinues PIII Study of Tasigna in GIST
April 25, 2011
- Wholesalers Less Pessimistic than Manufacturers about Quake's Effects on Demand
April 25, 2011
- Korosho Wants Industry “As a Whole”to Meet Power Cut Targets
April 25, 2011
- 4 Unapproved Indications Considered to Have Unmet Medical Needs: Council
April 25, 2011
- The Great East Japan Earthquake: MRs in the Disaster Zone
April 25, 2011
- No Company Subject to Penalty due to Failure to Develop Designated Unapproved Drugs/Indications
April 25, 2011
- Lantus Obtains 60% Market Share: sanofi-aventis
April 25, 2011
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…